Eli Lilly and Company $LLY Shares Sold by Galvin Gaustad & Stein LLC

Galvin Gaustad & Stein LLC lowered its position in shares of Eli Lilly and Company (NYSE:LLY) by 19.8% during the second quarter, Holdings Channel reports. The fund owned 1,263 shares of the company’s stock after selling 311 shares during the quarter. Galvin Gaustad & Stein LLC’s holdings in Eli Lilly and Company were worth $984,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of LLY. WestEnd Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock valued at $26,000 after purchasing an additional 21 shares during the last quarter. Wealth Preservation Advisors LLC acquired a new position in shares of Eli Lilly and Company in the 1st quarter valued at $27,000. Citizens National Bank Trust Department boosted its holdings in shares of Eli Lilly and Company by 180.0% in the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock valued at $35,000 after purchasing an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. acquired a new position in shares of Eli Lilly and Company in the 1st quarter valued at $40,000. Finally, TD Capital Management LLC boosted its holdings in shares of Eli Lilly and Company by 129.2% in the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after purchasing an additional 31 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes

LLY has been the topic of a number of research analyst reports. Leerink Partners reiterated a “market perform” rating and issued a $715.00 price target on shares of Eli Lilly and Company in a report on Thursday, August 7th. Wall Street Zen lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 20th. Berenberg Bank restated a “hold” rating and set a $830.00 target price (down previously from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. Daiwa America lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. Finally, Morgan Stanley reduced their target price on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating on the stock in a report on Friday, October 3rd. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have given a Hold rating to the company. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $948.56.

Insider Activity

In other news, Director J Erik Fyrwald purchased 1,565 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the purchase, the director directly owned 74,578 shares of the company’s stock, valued at approximately $47,903,686.74. This represents a 2.14% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Jamere Jackson purchased 200 shares of the company’s stock in a transaction that occurred on Friday, August 8th. The shares were purchased at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the purchase, the director directly owned 9,402 shares in the company, valued at $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought a total of 4,514 shares of company stock worth $2,894,841 over the last three months. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $833.08 on Friday. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $937.00. The company has a market capitalization of $788.47 billion, a price-to-earnings ratio of 54.45, a price-to-earnings-growth ratio of 1.19 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The firm’s fifty day moving average price is $742.42 and its 200 day moving average price is $766.36.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the previous year, the firm posted $3.92 EPS. The firm’s quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.